Overweight and Obesity Among People Living With HIV on Dolutegravir‐ and Efavirenz‐Based Therapies: A Comparative Cross‐Sectional Study DOI Creative Commons
Mohammed Jemal, Adane Adugna, Mamaru Getinet

et al.

AIDS Research and Treatment, Journal Year: 2024, Volume and Issue: 2024(1)

Published: Jan. 1, 2024

Background: Overweight and obesity have arisen as major public health challenges, affecting not just the general population but also people living with human immunodeficiency virus (HIV) (PLWH). Obesity being overweight are both risk factors for heart disease other related complications. However, little is known in our setting. As a result, this study was conducted to evaluate prevalence of its associated among PLWH on dolutegravir (DTG)‐ efavirenz (EFV)‐based therapies. Methods: An institution‐based comparative cross‐sectional carried out from June 30, 2021, August 2021. We purposively recruited 128 participants who been DTG ( n = 64)‐ EFV 64)‐based regimens ≥ 6 months. Demographic, anthropometric, laboratory, clinical data were collected using structured questionnaire. The entered into EpiData Version 4.6 analyzed SPSS 26.0. Multivariable logistic regression utilized identify that or obese, significance level set at p < 0.05. Result: 28.1% DTG‐prescribed 15.6% EFV‐prescribed participants. Age 40 years (adjusted odd ratio (AOR) 3.86; 95% confidence interval (CI): 1.08–13.73; 0.037), cluster differentiation 4 (CD4) T‐cell counts 500 cells/mm 3 (AOR 2.95; CI: 1.01–8.59; 0.029), insufficient physical activity 4.6; 1.53–13.84; 0.007) predictors obesity. Conclusion: uncommon ART. While difference statistically insignificant, higher patients treated compared those EFV. Older age, CD4 cell counts, healthcare providers must understand implications consider incorporating targeted weight control programs standard HIV treatment.

Language: Английский

Metabolic Complications After Initiating BIC/FTC/TAF Versus DTG + 3TC in ART-naive Adults With Human Immunodeficiency Virus (HIV): A Multicenter Prospective Cohort Study DOI Creative Commons
Alejandro García,

Miguel Suárez Robles,

Marı́a Jesús Pérez-Elı́as

et al.

Clinical Infectious Diseases, Journal Year: 2025, Volume and Issue: unknown

Published: March 28, 2025

Although antiretroviral therapy (ART) has become less toxic over time, its long-term adverse effects remain a concern. In ART-naive people, tenofovir alafenamide (TAF) is frequently prescribed to reduce the toxicity of disoproxil fumarate (TDF). However, metabolic impact TAF remains This study aimed evaluate in participants. We analyzed data from Cohort Spanish HIV Research Network (CoRIS). included participants who initiated either bictegravir/emtricitabine/TAF (BIC/FTC/TAF) or dolutegravir + lamivudine (DTG+ 3TC), matched by propensity score, after excluding those with hepatitis B. compared changes weight, biomarkers, and incidence metabolism-related clinical events 96 weeks. total, 340 were each group. The median age was 34 years, 95% male, 62% Western Europe. mean weight gain 1.4 kg (95% confidence interval [CI]: 1.1, 1.8) weeks, no significant differences between BIC/FTC/TAF DTG 3TC groups. Changes body mass index, lipid levels, hepatic steatosis (hypertension, diabetes mellitus, dyslipidemia, liver steatosis) also similar this nationwide cohort individuals, initiation resulted modest increases levels outcomes events. These findings suggest that profile should not be deciding factor when choosing 2- 3-drug ART regimens.

Language: Английский

Citations

1
Incidence and determinants of excessive weight gain in people living with HIV initiating tenofovir, lamivudine, and dolutegravir-based therapy: a multicenter retrospective study in northwest Ethiopia DOI Creative Commons
Gashaw Sisay Chanie,

Wagaye Atalay,

Tirsit Ketsela Zeleke

et al.

Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16

Published: April 4, 2025

Background The incidence and nature of excessive weight gain associated with antiretroviral treatment using tenofovir, lamivudine, dolutegravir based regimens among patients living human immunodeficiency virus has not been properly examined in Ethiopia. Therefore, this study aimed to assess the factors People on a real-world setting. Method A multicenter retrospective cross-sectional was conducted from December 1, 2022, August 30, 2023, involving 620 initiating regimen. Data sociodemographic, clinical details, were collected medical records patient interviews semi-structured questionnaire. Continuous variables reported mean standard deviation. Binary logistic regression analysis performed, P-value ≤0.25 included multivariate regression. Statistical significance set at ≤0.05. Results total participants involved analysis, revealing 31.43% 95%CI (27.1–36.0). 3.77 kg 1.5 SD 72 months follow-up. Factors such as being female [AOR = 1.75, 95% CI (1.01, 3.04)], age between 38–46 years 1.53, (1.23, 2.76)], lack physical activity 4.41, (1.46, 11.80)], having 6–12 13–24 since starting new regimen follow up duration 3.35, (2.79, 4.30)] 2.67, (2.43, 3.25)] respectively detectable viral load initiation 2.34, (1.18, 6.63)] significantly gain. Conclusion PLHIV receiving particularly females, aged 38–54 years, those limited activity, follow-up durations 6–24 months, advanced disease stages, therapy should be closely monitored for Proactive surveillance these groups is crucial optimize therapeutic outcomes address potential health concerns changes.

Language: Английский

Citations

0
Overweight and Obesity Among People Living With HIV on Dolutegravir‐ and Efavirenz‐Based Therapies: A Comparative Cross‐Sectional Study DOI Creative Commons
Mohammed Jemal, Adane Adugna, Mamaru Getinet

et al.

AIDS Research and Treatment, Journal Year: 2024, Volume and Issue: 2024(1)

Published: Jan. 1, 2024

Background: Overweight and obesity have arisen as major public health challenges, affecting not just the general population but also people living with human immunodeficiency virus (HIV) (PLWH). Obesity being overweight are both risk factors for heart disease other related complications. However, little is known in our setting. As a result, this study was conducted to evaluate prevalence of its associated among PLWH on dolutegravir (DTG)‐ efavirenz (EFV)‐based therapies. Methods: An institution‐based comparative cross‐sectional carried out from June 30, 2021, August 2021. We purposively recruited 128 participants who been DTG ( n = 64)‐ EFV 64)‐based regimens ≥ 6 months. Demographic, anthropometric, laboratory, clinical data were collected using structured questionnaire. The entered into EpiData Version 4.6 analyzed SPSS 26.0. Multivariable logistic regression utilized identify that or obese, significance level set at p < 0.05. Result: 28.1% DTG‐prescribed 15.6% EFV‐prescribed participants. Age 40 years (adjusted odd ratio (AOR) 3.86; 95% confidence interval (CI): 1.08–13.73; 0.037), cluster differentiation 4 (CD4) T‐cell counts 500 cells/mm 3 (AOR 2.95; CI: 1.01–8.59; 0.029), insufficient physical activity 4.6; 1.53–13.84; 0.007) predictors obesity. Conclusion: uncommon ART. While difference statistically insignificant, higher patients treated compared those EFV. Older age, CD4 cell counts, healthcare providers must understand implications consider incorporating targeted weight control programs standard HIV treatment.

Language: Английский

Citations

0